Although Adropin, as the genetic product of the ENHO gene, appears to have an overall pro-tumorigenic effect when administered exogenously, by activating VEGFR2 and PI3K/AKT signaling pathways, the upregulation of ENHO in situ appears to confer a net protective effect in pancreatic adenocarcinoma. The gene discussed is KDR; the disease is pancreatic adenocarcinoma.